Dostinex - a drug used to treat gynecological diseases.
Release form and composition
Dostinex is produced in the form of flat white oblong tablets, on one side of which there are markings “P” and “U”, separated by a notch, and on the other side engraving “700”, on top and bottom of which are short notches, 2 and 8 pieces each. in dark glass bottles.
The composition of one tablet contains 500 µg of cabergoline and such excipients as anhydrous lactose and leucine.
Indications for use
Dostinex is used to prevent physiological lactation after childbirth and suppress already established postpartum lactation, as well as in the following cases:
- Idiopathic hyperprolactinemia;
- Empty Turkish saddle syndrome (in combination with hyperprolactinemia);
- Prolactin secreting pituitary adenomas;
- Treatment of disorders directly associated with hyperprolactinemia.
The use of Dostinex is contraindicated in children under 16 years of age, as well as in cases of hypersensitivity to the active and auxiliary components that make up the product.
With caution, the drug is prescribed for hypertension that developed during pregnancy, Raynaud's syndrome, severe cardiovascular diseases, as well as in the following cases:
- Peptic ulcers;
- Severe cognitive or psychotic disorders;
- Gastrointestinal bleeding;
- Simultaneous use with drugs that have a hypotensive effect;
- Severe liver failure;
- Symptoms of dysfunction of respiration and heart, resulting from fibrotic changes.
In pregnancy, the use of the drug is permissible only in cases where the expected effect of therapy for a woman far exceeds the potential risk to the developing fetus.
Dostinex should not be given to mothers with disorders associated with hyperprolactinemia who want to breastfeed.
Dosing and Administration
Tablets are taken orally during the meal, washed down with a small amount of water.
The dosage of Dostinex to prevent lactation is 2 tablets once a day after birth.
Patients to suppress established lactation take half a pill (0.25 mg) twice a day every 12 hours for 2 days.
In cases of disorders associated with hyperprolactinemia, the initial dose of the drug is 0.5 mg once every 7 days, with a further increase in dose of 0.5 mg to achieve the optimal therapeutic effect.
The instructions to Dostineks indicated that the drug may cause side effects from some body systems, namely:
- Orthostatic hypotension, palpitations and asymptomatic reduction in blood pressure (cardiovascular system);
- Vertigo, dizziness, depression, asthenia, fatigue, headache, paresthesia, drowsiness, and fainting (nervous system);
- Gastritis, nausea, constipation, vomiting, dyspepsia, abdominal pain and epigastric pain (digestive system).
Dostinex can also cause:
- Nose bleed;
- Flushing of the skin of the face;
- Transient hemianopia;
- Cramps in the muscles of the lower limbs;
- Respiratory disorders;
- Respiratory failure;
- Impaired liver function;
- The increase in the activity of creatinine-phosphokinase in the blood.
Symptoms of Dostinex overdose are nausea, hallucinations, vomiting, confusion, dyspepsia, psychosis and orthostatic hypotension.
In such cases, gastric lavage, maintenance of blood pressure and, if necessary, the appointment of dopamine antagonists are required.
Before using Dostinex in the treatment of disorders associated with hyperprolactinemia, a complete study of the function of the pituitary gland should be carried out.
In cases of increasing the dosage of the drug to establish the lowest effective dose, providing a therapeutic effect, patients should be under medical supervision. Further, after selecting an effective dosing regimen, it is necessary to regularly determine the concentration of prolactin in the blood serum once a month. In most cases, the normalization of prolactin levels is observed within 14-28 days of therapy.
Typically, after discontinuation of the drug in patients there is a relapse of hyperprolactinemia, however, in some cases there is a persistent suppression of the level of prolactin over several months. Ovulatory cycles in most patients after the cancellation of Dostinex persist for at least six months.
Children under the age of 16 should not be prescribed the drug due to the fact that the safety and efficacy of using the drug in patients of this age group have not been established.
During the period of drug therapy, patients should refrain from conducting potentially hazardous activities that require increased attention and speed of psychomotor reactions.
Due to the fact that the drug in patients with Parkinson's disease may cause a sudden sleep, it is recommended to prescribe Dostinex in the smallest doses.
It should be borne in mind that the simultaneous use of Dostinex with other ergot alkaloids, drugs acting as dopamine antagonists, as well as macrolide antibiotics is not recommended.
Drug synonyms are not released. The counterparts of Dostinex include Bergolak and Agalates.
Terms and conditions of storage
In accordance with the instructions, Dostinex must be stored in a well-ventilated, protected from light, dry and out of reach of children, at a temperature not exceeding 25 ºС.
From pharmacies, the drug is released on prescription. The shelf life of tablets, subject to the basic recommendations of the manufacturer, is two years.